OBR OncologyIbrutinib Outperforms ASCT in Treatment-Naive MCL

Patients with previously untreated mantle cell lymphoma (MCL) have relied on autologous stem cell transplant (ASCT) for more than 20 years; the current standard of care entails high-dose cytarabine-containing chemoimmunotherapy, ASCT, and rituximab maintenance. A recent clinical trial’s findings, which revealed that FFS was superior to ASCT when ibrutinib medication was added, may change this.